(Q42452730)

31 October 2017

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle (English)

1 reference

31 October 2017

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

1 April 2024

author name string

B. Berman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616354

1 April 2024

T. Sullivan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616354

1 April 2024

T. De Araujo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616354

1 April 2024

M. Nadji

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616354

1 April 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

31 October 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.0366-077X.2003.05634.x

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.0366-077X.2003.05634.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

British Journal of Dermatology

1 April 2024

published in

1 reference

31 October 2017

149 Suppl 66

1 reference

31 October 2017

59-61

1 reference

CD95's deadly mission in the immune system

31 October 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Imiquimod: an immune response modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Laminin receptor in lymph node negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0366-077X.2003.05634.X

Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L).

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

Cytokine induction by the immunomodulators imiquimod and S-27609

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

Imiquimod 5% cream (Aldara).

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

Nonmelanoma cancers of the skin

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

Guidelines of care for alopecia areata

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.0366-077X.2003.05634.X

1 April 2024

Identifiers

1 reference

31 October 2017

1 reference